Australia's most trusted
source of pharma news
Posted 2 August 2022 PM
CSL has finally completed its mammoth Vifor acquisition, after two delays due to regulatory speed bumps.
In December last year CSL announced the AU$17.2 billion buy of the Swiss pharma to get a solid position in the renal market. Expected to be closed by March, the settlement was postponed for four months until 22 July. Then on 13 July it was again postponed, to 30 September, waiting on regulatory clearances.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.